(Q33337674)

25 July 2017

title

Single-agent gemcitabine in patients with resistant small-cell lung cancer (English)

1 reference

25 July 2017

1 reference

6

P E Postmus

1 reference

25 July 2017

I van der Lee

1

1 reference

25 July 2017

E F Smit

2

1 reference

25 July 2017

J W van Putten

3

1 reference

25 July 2017

H J Groen

4

1 reference

25 July 2017

N J Schlösser

5

1 reference

25 July 2017

F M Schramel

7

1 reference

25 July 2017

publication date

1 April 2001

1 reference

25 July 2017

1 reference

25 July 2017

volume

12

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

557-561

1 reference

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Second-line chemotherapy and its evaluation in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Confidence intervals for reporting results of clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011104509759

7 January 2021

Identifiers

DOI

10.1023/A:1011104509759

1 reference

release_mdrobsl6nfhvpddtzy2l2b4igi

25 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mdrobsl6nfhvpddtzy2l2b4igi

24 November 2022

mapped directly with Wikidata item

1 reference